new_0222_0695|CNTB|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0695|CNTB|Long Name|1|1|Connect Biopharma Holdings Ltd Total Current Assets (Quarterly) (USD)|Connect Biopharma Holdings Ltd Cash and Short Term Investments (Quarterly) (USD)|Connect Biopharma Holdings Ltd Inventories (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net PP&E (Quarterly) (USD)|Connect Biopharma Holdings Ltd Goodwill and Intangibles (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Current Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Long Term Liabilities (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Deposits (Quarterly) (USD)|Connect Biopharma Holdings Ltd Book Value (Quarterly) (USD)|Connect Biopharma Holdings Ltd Retained Earnings (Quarterly) (USD)|Connect Biopharma Holdings Ltd Treasury Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd EV to Revenues|Connect Biopharma Holdings Ltd EV to Earnings|Connect Biopharma Holdings Ltd EV to Free Cash Flow|Connect Biopharma Holdings Ltd EV to Assets (Quarterly)|Connect Biopharma Holdings Ltd PS Ratio|Connect Biopharma Holdings Ltd PE Ratio|Connect Biopharma Holdings Ltd Price to Book Value|Connect Biopharma Holdings Ltd PEG Ratio|Connect Biopharma Holdings Ltd Debt to Equity Ratio|Connect Biopharma Holdings Ltd Dividend Yield|Connect Biopharma Holdings Ltd Shareholder Yield (TTM)|Connect Biopharma Holdings Ltd Percent of Shares Outstanding Short|Connect Biopharma Holdings Ltd Total Receivables (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Payables (Quarterly) (USD)|Connect Biopharma Holdings Ltd Total Capital Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd Return on Invested Capital|Connect Biopharma Holdings Ltd Quality Ratio Score|Connect Biopharma Holdings Ltd Momentum Score|Connect Biopharma Holdings Ltd Beta (1Y)|Connect Biopharma Holdings Ltd Sustainable Growth Rate (TTM)|Connect Biopharma Holdings Ltd Institutional Investor Ownership Percentage|Connect Biopharma Holdings Ltd Average Diluted Shares Outstanding (Quarterly)|Connect Biopharma Holdings Ltd Total Employees (Annual)|Connect Biopharma Holdings Ltd EPS Diluted (Quarterly) (USD)|Connect Biopharma Holdings Ltd SG&A Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Shares Outstanding|Connect Biopharma Holdings Ltd Repurchase of Capital Stock (Quarterly) (USD)|Connect Biopharma Holdings Ltd Ordinary Shares Number (Quarterly)|Connect Biopharma Holdings Ltd Payout Ratio|Connect Biopharma Holdings Ltd Quick Ratio (Quarterly)|Connect Biopharma Holdings Ltd Normalized Diluted EPS (Quarterly) (USD)|Connect Biopharma Holdings Ltd Stock Buybacks (Quarterly) (USD)|Connect Biopharma Holdings Ltd Effective Tax Rate (TTM)|Connect Biopharma Holdings Ltd Return on Equity|Connect Biopharma Holdings Ltd Net Income (TTM) (USD)|Connect Biopharma Holdings Ltd Revenue (TTM) (USD)|Connect Biopharma Holdings Ltd Dividend Per Share (Quarterly) (USD)|Connect Biopharma Holdings Ltd Revenue (Quarterly) (USD)|Connect Biopharma Holdings Ltd Gross Profit (Quarterly) (USD)|Connect Biopharma Holdings Ltd Pre-Tax Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Net Interest Income (Quarterly) (USD)|Connect Biopharma Holdings Ltd Price (USD)|Connect Biopharma Holdings Ltd Total Return Price (USD)|Connect Biopharma Holdings Ltd Enterprise Value (USD)|Connect Biopharma Holdings Ltd 30-Day Average Daily Volume|Connect Biopharma Holdings Ltd 1 Year Price Returns (Daily)|Connect Biopharma Holdings Ltd Short Interest|Connect Biopharma Holdings Ltd PE Ratio (Forward)|Connect Biopharma Holdings Ltd PE Ratio (Forward 1y)|Connect Biopharma Holdings Ltd PS Ratio (Forward)|Connect Biopharma Holdings Ltd PS Ratio (Forward 1y)|Connect Biopharma Holdings Ltd Quarterly EPS Estimates (USD)|Connect Biopharma Holdings Ltd Quarterly Revenue Estimates (USD)|Connect Biopharma Holdings Ltd Quarterly EPS Surprise|Connect Biopharma Holdings Ltd Quarterly Revenue Surprise|Connect Biopharma Holdings Ltd Quarterly Actual EPS (USD)|Connect Biopharma Holdings Ltd Quarterly Actual Revenue (USD)|Connect Biopharma Holdings Ltd Revenue Estimates for Current Fiscal Year (USD)|Connect Biopharma Holdings Ltd Revenue Estimates for Next Fiscal Year (USD)|Connect Biopharma Holdings Ltd Price Target (USD)|Connect Biopharma Holdings Ltd Consensus Recommendation|Connect Biopharma Holdings Ltd Price Target Num Estimates|Connect Biopharma Holdings Ltd EPS Estimates for Current Fiscal Year (USD)|Connect Biopharma Holdings Ltd EPS Estimates for Next Fiscal Year (USD)|Connect Biopharma Holdings Ltd Research and Development Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Reconciled Depreciation (Quarterly) (USD)|Connect Biopharma Holdings Ltd Non-Operating Interest Expense (Quarterly) (USD)|Connect Biopharma Holdings Ltd Land and Improvements (Quarterly) (USD)|Connect Biopharma Holdings Ltd Buildings and Improvements (Quarterly) (USD)|Connect Biopharma Holdings Ltd Other Properties (Quarterly) (USD)|Connect Biopharma Holdings Ltd Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0695|CNTB|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0695|CNTB||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0695|CNTB||5|5|181|181|0|181|181|181|181|181|0|181|181|181|0|0|1.44206008584|0|0|0|1.43827160494|0|0|1.44206008584|0|15.3|181|181|181|0|0|0|0|0|30.6|0|0|0|0|22|0|181|0|0|0|0|181|0|181|0|0|0|0|0|0|0|1.44206008584|1.44206008584|1.44206008584|1.44117647059|0|15.3|0|0|0|0|91|91.3333333333|0|0|0|0|98|147|51.6666666667|23.8461538462|51.6666666667|73.5|89.3333333333|0|0|0|0|0|181|181
new_0222_0695|CNTB||6|6|1|1|0|1|1|1|1|1|0|1|1|1|0|0|233|0|0|0|162|0|0|233|0|20|1|1|1|0|0|0|0|0|10|0|0|0|0|5|0|1|0|0|0|0|1|0|1|0|0|0|0|0|0|0|233|233|233|204|0|20|0|0|0|0|1|6|0|0|0|0|3|2|6|13|6|4|3|0|0|0|0|0|1|1
new_0222_0695|CNTB||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0695|CNTB|202012|202012|202012|161.7558|156.6045||2.6737|0.0523|322.9323|5.8159|317.1165||-156.8801|-163.9816|0.0005|||||||||||||0.265|4.4852|0.0037|||||||||||||53.9417|||||0||-116.7848||||||||||||||||||||||||||||||||||||1.0104|0.0895
new_0222_0695|CNTB|202102|202012|202012|||||||||||||||||||||||||||||||||||62|||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0695|CNTB|202103|202103|202103|||||||||||||||-33.6049|||||||0||1.3438|||||||||50.5254|||||57.5042|||||||||||||||||18.5|18.5|907.2232|||772727|||||-0.21|0||||||||||||||||||
new_0222_0695|CNTB|202104|202103|202103|||||||||||||||-28.8549|||||||0||1.2664|||||||||51.9083||||||||||||||||||||||16.27|16.27|778.9889|280236.3333||728246|||||||||||0|0|29.6667|1.3333|3|-1.13|-2.15|||||||
new_0222_0695|CNTB|202105|202103|202103|||||||||||||||-25.8942|||||||0||1.2784|||||||||52.3253||||||||||||||||||||||14.88|14.88|699.058|65393.1||735124||||||||||||||||||||||||
new_0222_0695|CNTB|202106|202106|202106|324.504|313.228||6.182|3.4793|14.0923|14.0178|0.0746||322.1331|-311.4919|0.0005|||-12.324||||3.4851|||0||1.3481|0.408|10.4865|0.0102||||||57.416|||||57.4834||57.4834|||||0||-252.0471||||||||19.53|19.53|809.4228|53303.7||774912|||||-0.25|0||||||||1.3333|||||||||3.4303|0.5493
new_0222_0695|CNTB|202107|202106|202106|||||||||||||||-14.4945||||3.9276|||0||1.3423|||||||||58.7168||||||||||||||||||||||22.01|22.01|951.9816|80626.0333||771572|||||||||||0|0|29|1.25|4|-1.007|-1.7185|||||||
new_0222_0695|CNTB|202108|202106|202106|||||||||||||||-15.7724||||4.1881|||0||1.4816|||||||||58.5876||||||||||||||||||||||23.47|23.47|1035.9074|61048.8333||851674||||||||||||||||||||||||
new_0222_0695|CNTB|202109|202109|202109|||||||||||||||-16.4375||||4.3237|||0||1.4877|||||||||60.8678||||||||||||||||||||||24.23|24.23|1079.5947|52399.2||855165||||||0|||||||29.25|1.25|4|-3.77|-1.8485|||||||
new_0222_0695|CNTB|202110|202109|202109|||||||||||||||-9.0944||||2.8266|||0||2.4246|||||||||60.6205||||||||||||||||||||||15.84|15.84|597.309|117105.3667||1393757||||||||||||||1.25||||||||||
new_0222_0695|CNTB|202111|202109|202109|||||||||||||||0.9619||||0.7762|||0||0.0721|||||||||60.2204||||||||||||||||||||||4.35|4.35|-63.1752|474231.3333||41453||||||||||||||1.25||||||||||
new_0222_0695|CNTB|202112|202112|202112|||||||||||||||0.2617||||0.919|||0||0.4739|||||||||60.1264||||||||||||||||||||||5.15|5.15|-17.1885|619008.8||272408||||||0|||||0|||||||||||||
new_0222_0695|CNTB|202201|202112|202112|||||||||||||||0.7431||||0.8209|||0||0.5508|||||||||55.8665||||||||||||||||||||||4.6|4.6|-48.8044|437147.6||316607|||||||||||||23.25|1.25|4|-1.7335|-2.31|||||||
new_0222_0695|CNTB|202202|202112|202112|||||||||||||||0.8218||||0.8048|||0|||||||||||||||||||||||||||||||||4.51|4.51|-53.9779|153895.9667|||||||||||||0|0|22|1.3333|3|-2.18||||||||
new_0222_0695|CNTB|202203|202203|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0695|CNTB|202206|202206|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||
new_0222_0695|CNTB|202209|202209|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||0||||||||||||||||||